KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
KORU Medical Systems Full Year 2023 Earnings: EPS Misses Expectations
Buy Rating Affirmed for REPRO-MED Systems on Strong Growth Prospects and Innovative Expansion
Buy Rating Justified: REPRO-MED Systems’ Strong Growth Prospects and Solid Financial Performance
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
Craig-Hallum Keeps Their Buy Rating on REPRO-MED Systems (KRMD)
Lake Street Sticks to Their Buy Rating for REPRO-MED Systems (KRMD)
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
Buy Rating Affirmed for KORU Medical Systems Amidst Growth and Market Expansion Prospects
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.